StopDown
Angel investor

Mukesh Bansal

Mukesh Bansal took part in 2 disclosed rounds in Indian startups in 2026 (0 as lead), most often Series A rounds in AI & Deep Tech; its latest was Superleap on 4 August 2026.

2Indian companies
2StopDown stories

About Mukesh Bansal

Mukesh Bansal has backed Indian startups that StopDown covered, listed below.

Deals in 2026

Deals in 2026
DateCompanyRoundAmountRoleCo-investorsStory
4 August 2026SuperleapSuperleappre-Series A₹36 Cr ($3.7M)ParticipantPeak XV Partners, Nikhil Kamath, Supermorpheus Group, Gaurav Munjal, Anupam MittalStory
7 March 2026Nurix AISeries AParticipantProsus, General Catalyst (India), AccelStory

Stage and sector mix

Disclosed rounds Mukesh Bansal took part in, by stage and by sector.

Stage and sector mix
Stage20262025
Series A20
Stage and sector mix
Sector20262025
AI & Deep Tech10
Enterprise Software & IT10

Frequent co-investors

Frequent co-investors
InvestorRounds together
Accel1
Anupam Mittal1
Gaurav Munjal1
General Catalyst (India)1
Nikhil Kamath1
Peak XV Partners1
Prosus1
Supermorpheus Group1

Exits and IPOs in the portfolio

Exits and IPOs in the portfolio
CompanyEventLatest storyDate
Nurix AIAcquisition / mergerNurix AI acquires Verloop.io to expand enterprise AI platform9 July 2026

Indian portfolio

Showing 2

India-based companies only. Linked names have a StopDown page; the rest link up on their own as soon as we cover them.

Mukesh Bansal in the news

Questions about Mukesh Bansal

How many investments did Mukesh Bansal make in India in 2026?

StopDown has recorded 2 disclosed rounds in Indian startups with Mukesh Bansal in 2026 so far, 0 of them as lead. The latest was Superleap on 4 August 2026 (₹36 Cr ($3.7M)).

Which sectors does Mukesh Bansal invest in?

In the 2025 and 2026 rounds StopDown recorded, Mukesh Bansal invested most often in AI & Deep Tech (1 round) and Enterprise Software & IT (1 round).

Does Mukesh Bansal lead rounds?

In the 2 rounds StopDown recorded in 2025 and 2026, Mukesh Bansal joined as a participant; none named it as the lead.